Showing 1491-1500 of 2314 results for "".
- Our Tears Could One Day Tell Us If We Have Glaucomahttps://modernod.com/news/our-tears-could-one-day-tell-us-if-we-have-glaucoma/2476643/Contrary to what many think, high pressure inside the eye does not define glaucoma and investigators want to know if the proteins circulating in the fluid of our eyes might, according to researchers at the Medical College of Georgia at Augusta University. While some patients do have classi
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment. That’s why Johnson
- A Daily Orange May Reduce AMD Risk, Study Findshttps://modernod.com/news/a-daily-orange-may-reduce-amd-risk-study-finds/2479986/People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with those who do not eat oranges, a study has found, according to a report in Medscape.
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Forbes: Will Your iPhone’s Dark Mode Save Your Eyes?https://modernod.com/news/forbes-will-your-iphones-dark-mode-save-your-eyes/2476786/Eye care has come a long way. From cataract surgery to Lasik, we can do more than ever before to return sight to those who once would have lost it. These days, it seems like there’s always a new breakthrough around the corner—here’s a roundup of some of the biggest trends in eye care and what the
- SightGlass Vision Reports on 2-Year Chinese Study for DOT Spectacle Lenses for Myopiahttps://modernod.com/news/sightglass-vision-reports-on-2-year-chinese-study-for-dot-spectacle-lenses-for-myopia/2486985/Key Takeaways SightGlass Vision’s DOT spectacle lenses reduced myopia progression by more than 1D on average after 2 years in Chinese children aged 6 to 10
- Low-Dose Atropine Shows Promise in Slowing Childhood Myopia, Real-World Study Findshttps://modernod.com/news/low-dose-atropine-shows-promise-in-slowing-childhood-myopia-real-world-study-finds/2486653/A new clinical study published in Frontiers in Pharmacology adds to growing evidence that low-dose atropine eye drops can
- iVeena Doses First Participant in Phase 1 Trial of IVMED-85 for Myopia Progressionhttps://modernod.com/news/iveena-doses-first-participant-in-phase-1-trial-of-ivmed-85-for-myopia-progression/2485668/iVeena Delivery Systems announced that the first patient has been dosed in its phase 1, first-in-human clinical study of IVMED-85 in healthy adult volunteers. The phase 1 trial is designed to evaluate the safety and tolerabili
- VIEW Optometry Launches Doctor-Led Alliance to Protect Independent Optometry Practiceshttps://modernod.com/news/view-optometry-launches-doctor-led-alliance-to-protect-independent-optometry-practices/2485609/Key Takeaways VIEW Optometry is a new, doctor-founded alliance committed to protecting clinical aut